UCB and PAREXEL Sign Strategic Partnership Agreement
PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has been selected as one of two strategic partners by UCB, to provide clinical development services worldwide. PAREXEL will work with UCB to drive innovation and accelerate development, as well as to increase productivity and cost effectiveness.







